about
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionPARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsClinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C statusComparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer PatientsGenotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerWhat do women with gynecologic cancer know about HPV and their individual disease? A pilot study.A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability.The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.Immunohistochemical expression of BRCA1 and lethal prostate cancer.Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families.The inherited genetics of ovarian and endometrial cancer.Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancerHMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genesAGO Austria recommendations for genetic testing of patients with ovarian cancer.BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells.Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.Identifying post-menopausal women at elevated risk for epithelial ovarian cancerLavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.Adequacy of family history taking in ovarian cancer patients: a population-based study.High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testingGenetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyondBRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic CounselingCADD score has limited clinical validity for the identification of pathogenic variants in noncoding regions in a hereditary cancer panel.BRCA1 and microRNAs: emerging networks and potential therapeutic targets.BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications.Novel therapies, including enzastaurin, in the treatment of ovarian cancer.Ubiquitination involved enzymes and cancer.Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age.Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis.Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan.
P2860
Q26744525-4EFDD1A0-BFB5-4BF4-B1AE-B98440B19570Q28071345-106CD144-7C81-478A-8187-00646A87E0D8Q28307436-68E09CCB-EDA7-4807-9046-3B754A13AFCAQ33584055-F708F014-9560-4FDD-AC1E-07C4263A81A1Q33620683-64C0C1F9-4821-4040-ADFE-2FE2581F52B3Q33704050-F0C037F0-DC5D-4B89-BF96-399BDB184931Q33716245-AB215DCC-E54D-4448-B82B-FC154734892DQ33759047-0813E386-2781-4046-A252-A2EAC56332CBQ33792732-93E0F176-27D1-4F55-9B65-0727F75DBA3DQ33991747-F2C05506-129F-4DA9-BDFD-B94F34F3AB7FQ34059765-21F904BA-0AA3-4D31-BF17-180C76842DF9Q34380980-0B6BE12E-C367-4176-9953-C106403E614DQ34626692-1363271F-AFCB-4BE4-9691-525DF1F99755Q34639149-A3DA445A-F744-4BBE-AD75-206160BDA8B1Q34737253-31BDC02B-4CCD-4163-88E2-9023D2958047Q34773464-338A1281-2743-45D1-AFA5-9D4CC316C34FQ34775177-06AA2176-1433-465A-81EC-81F708DEA62DQ34910918-BD252F03-3F7F-4EEB-B104-4FCECE2B00D4Q35615694-3FE4ACA5-B194-4BF9-B6AF-DDCD18E27F5FQ35952600-1B2B7414-AD90-429B-A2BD-8E4A4E8D2871Q36017531-385663BA-FCB8-45E2-92EF-4754C13D43AFQ36117690-ABCBD347-92B7-4DB8-A29C-EE1D27827509Q36190966-654AFD64-2878-447D-907F-1A453E94433EQ36331643-05F49C51-9E0E-49F6-8CAF-02975BE33D45Q36369334-0C5A73CE-56FA-4879-868B-DC4F852E8E70Q36394349-AA7EE01C-428E-4B20-BEF7-C95C471EC5DAQ36474986-015A2483-96C5-4933-A7C2-F583BBB29F28Q36619933-FC8B95F8-637F-40F1-8148-CB918676F685Q36714988-42D2C807-7688-4C48-874E-08E191BFDC4EQ36906183-09F48304-5A56-46DF-9F63-64C432A581A6Q37396615-59BE0E7F-A6F0-4FE2-AD1F-A90E54A71666Q37461841-DF178C04-1D2D-4156-9109-851FB57873E9Q37770590-46072DE4-4402-4D1F-AF0F-4BBF4FA6CF2DQ38198095-C3484492-FD15-44FF-A95B-ED9A2347FD2BQ38229325-B85E9783-F681-428A-8DD4-1A3D657E04EAQ38340008-777B80D8-DD8E-45DC-B960-1D367B206B4DQ38663391-17681FD0-F444-4455-81E7-D5E94E21BDD8Q38796779-FE9F90D1-4ACB-4CC8-BCE8-00ACA3283C09Q41524271-92516C26-E056-493E-8DFA-1BCB8F6B9710Q44039104-7430FFF6-6699-40D6-9C7F-C61418516DB1
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The contribution of BRCA1 and BRCA2 to ovarian cancer.
@en
The contribution of BRCA1 and BRCA2 to ovarian cancer.
@nl
type
label
The contribution of BRCA1 and BRCA2 to ovarian cancer.
@en
The contribution of BRCA1 and BRCA2 to ovarian cancer.
@nl
prefLabel
The contribution of BRCA1 and BRCA2 to ovarian cancer.
@en
The contribution of BRCA1 and BRCA2 to ovarian cancer.
@nl
P2860
P1433
P1476
The contribution of BRCA1 and BRCA2 to ovarian cancer.
@en
P2093
Simon A Gayther
P2860
P304
P356
10.1016/J.MOLONC.2009.02.001
P577
2009-02-10T00:00:00Z